Advanced Filters
noise

Additional Locations, Utah Clinical Trials

A listing of Additional Locations, Utah clinical trials actively recruiting patient volunteers.

Found 284 clinical trials
S Site Public Contact

Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors

The goal of this clinical trial is to learn if an investigational drug CP-383 works to treat advanced cancer. It will also learn about the safety of CP-383. The main questions if aims to answer are: Does CP-383 slow or stop the growth of cancer in patients with advanced cancer …

18 years of age All Phase 1/2
M Mohammadreza Heidari

A Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-antihistamines

This is a US, multi-center, randomized, double-blind, double-dummy, Phase 3b study to evaluate efficacy of remibrutinib (25 mg twice daily \[b.i.d.\] by mouth \[p.o.\]) compared to dupilumab (600 mg loading dose administered subcutaneously (s.c.) followed by 300 mg every 2 weeks s.c.) at early timepoints (4 weeks and earlier), when …

18 years of age All Phase 3

Cadisegliatin as Adjunctive Therapy to Insulin in Participants With Type 1 Diabetes

This is a Phase 3 trial of cadisegliatin as adjunctive therapy to insulin in participants with Type 1 Diabetes Mellitus.

18 years of age All Phase 3
G Genesis Guzman

Phase 2b Study of EVO756 in Adults With Atopic Dermatitis

This study will evaluate the efficacy and safety of different doses of EVO756 in adults with moderate to severe atopic dermatitis.

18 years of age All Phase 2
J JBR Patient Inquiries

A Phase 1 Study of ARC-001 in Participants Undergoing Third Molar Extraction

The study will test the investigational product gel against placebo (which contains no active ingredient) to determine if it is safe after wisdom tooth extraction. The main questions the study will answer are: How much of the investigational product is absorbed in the blood? Are there side effects?

18 - 55 years of age All Phase 0
A Amelia Millward

Live and Interactive Fitness Training Program (Vivo Knee OA)

Potential participants will be screened at clinic. Patients who meet eligibility criteria will be considered for study. After written informed consent is obtained, participants will complete baseline testing and participants who meet eligibility criteria will be randomized 1:1 to 2 treatment arms: Vivo Arm: Vivo twice a week for 6 …

55 - 85 years of age All Phase N/A
S Site Public Contact

A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors

The goal of this open-label dose escalation and expansion study is to evaluate the safety and tolerability of NKT5097 in adults with advanced/metastatic tumors (emphasis on breast cancer and solid tumors with CCNE1 amplification). Main questions to answer include: What is the recommended dose for expansion and/or Phase 2 What …

18 years of age All Phase 1
I Isabel Jimenez, RN, MSN

Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumors

This is a multicenter, open-label FIH, Phase 1a (dose escalation), Phase 1b (dose expansion) and Phase 2 study in patients with advanced metastatic solid tumors refractory to standard treatment.

18 years of age All Phase 1/2

A Study in Adult Participants With EoE to Evaluate Vonoprazan 20 mg Compared to Placebo After 12 Weeks and to Evaluate Vonoprazan 20 mg Up to 24 Weeks

The primary objective of this study is to assess the efficacy of vonoprazan 20 mg once daily (QD) compared to placebo QD in the number of participants with a peak eosinophilic histologic response \<15 eosinophils per high-power field (eos/hpf) after 12 weeks of therapy.

18 years of age All Phase 2
N Nehal Lakhani

First-in-Human Trial of VBC101 in Participants With Advanced Solid Tumor Malignancies

This is a multicenter, open-label, multiple-dose, FIH Phase 1/2a trial. The Phase 1 portion adopts an accelerated titration for the first dose level, followed by BOIN design to identify the MTD and/or RP2D with potential backfill cohorts. The Phase 2a portion consists of dose optimization followed by cohort expansion to …

18 years of age All Phase 1/2

Simplify language using AI